KR950016741A - 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법 - Google Patents

체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법 Download PDF

Info

Publication number
KR950016741A
KR950016741A KR1019940034932A KR19940034932A KR950016741A KR 950016741 A KR950016741 A KR 950016741A KR 1019940034932 A KR1019940034932 A KR 1019940034932A KR 19940034932 A KR19940034932 A KR 19940034932A KR 950016741 A KR950016741 A KR 950016741A
Authority
KR
South Korea
Prior art keywords
compound
formula
weight loss
hydrochloride
curb
Prior art date
Application number
KR1019940034932A
Other languages
English (en)
Inventor
울만 브리안트 헨리
알란 도지 제프리
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016741A publication Critical patent/KR950016741A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

유효량의 하기 일반식( I )의 화합물을 사람에 투여함을 포함하는, 체중 손실을 유도하거나 용이하게 하거나 또는 체중 증가를 억제하는 방법:
상기식에서,
Rl및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.

Description

체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 체중 중가를 억제하거나 또는 체중 감소를 유도하는 데 사용하기 위한, 하기 일반식( I )의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 군으로부터 선택된다.
  2. 제1항에 있어서, 상기 화합물이 그의 염산염인 화합물.
  3. 제1항에 있어서, 예방 목적으로 투여하는 화합물.
  4. 제1항에 있어서, 상기 화합물이
    또는 그의 염산 염인 화합물.
  5. 식욕을 억제하는 데 사용하기 위한 하기 일반식( I )의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 치환되거나 비치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 군으로부터 선택된다.
  6. 제5항에 있어서, 상기 화합물이 그의 염산염인 화합물.
  7. 제5항에 있어서, 예방 목적으로 투여하는 화합물.
  8. 제5항에 있어서, 상기 화합물이
    또는 그의 염산염인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940034932A 1993-12-21 1994-12-19 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법 KR950016741A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,291 1993-12-21
US08/171,291 US5578613A (en) 1993-12-21 1993-12-21 Methods for inhibiting weight gain or inducing weight loss

Publications (1)

Publication Number Publication Date
KR950016741A true KR950016741A (ko) 1995-07-20

Family

ID=22623225

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940034932A KR950016741A (ko) 1993-12-21 1994-12-19 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법

Country Status (16)

Country Link
US (2) US5578613A (ko)
EP (1) EP0659423A1 (ko)
JP (1) JPH07196492A (ko)
KR (1) KR950016741A (ko)
CN (1) CN1107707A (ko)
AU (1) AU8154094A (ko)
CA (1) CA2138455A1 (ko)
CZ (1) CZ322294A3 (ko)
HU (1) HUT71342A (ko)
IL (1) IL112044A (ko)
NO (1) NO944923L (ko)
NZ (1) NZ270182A (ko)
PH (1) PH31266A (ko)
RU (1) RU94044357A (ko)
TW (1) TW272126B (ko)
ZA (1) ZA9410090B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
AU751158B2 (en) 1998-06-16 2002-08-08 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
EP1789806A2 (en) * 2004-09-13 2007-05-30 Lipomics Technologies, Inc. Metabolite markers for weight management
WO2006050999A2 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
PL2225261T3 (pl) 2007-12-03 2016-09-30 Inhibitory boropeptydowe enteropeptydaz i ich zastosowania w leczeniu otyłości, nadwagi i/lub chorób związanych z nieprawidłowym metabolizmem tłuszczów
WO2013102207A1 (en) * 2011-12-30 2013-07-04 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW303299B (ko) * 1993-07-22 1997-04-21 Lilly Co Eli

Also Published As

Publication number Publication date
PH31266A (en) 1998-06-18
IL112044A0 (en) 1995-03-15
EP0659423A1 (en) 1995-06-28
US5578614A (en) 1996-11-26
RU94044357A (ru) 1996-10-20
TW272126B (ko) 1996-03-11
NO944923L (no) 1995-06-22
ZA9410090B (en) 1996-06-19
NO944923D0 (no) 1994-12-19
JPH07196492A (ja) 1995-08-01
CN1107707A (zh) 1995-09-06
NZ270182A (en) 1996-08-27
AU8154094A (en) 1995-06-29
IL112044A (en) 1999-01-26
CZ322294A3 (en) 1995-09-13
HUT71342A (en) 1995-11-28
US5578613A (en) 1996-11-26
CA2138455A1 (en) 1995-06-22
HU9403673D0 (en) 1995-02-28

Similar Documents

Publication Publication Date Title
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016731A (ko) 지루 및 좌창의 억제 방법
RU97108050A (ru) Способ ингибирования состояний, связанных с нейропептидом y
KR950010892A (ko) 자궁 섬유증 억제 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016722A (ko) Ldl 산화 및 죽상동맥경화증의 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016743A (ko) 마이엘로퍼옥시다제 활성을 억제하는 방법
KR950016733A (ko) 난소 발육부전, 사춘기 지연, 또는 성적 유치증의 억제방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid